Finding a Pancreatic Cancer Biomarker


BIDMC is leading a new, worldwide consortium named Project Survival to discover a clinically-meaningful biomarker to cure pancreatic cancer.

FemalePancreasIllus

The Pancreas and Liver Institute has formed a “Dream Team” of expert centers represented by the Pancreatic Cancer Research Team (PCRT) in concert with Cancer Research And Biostatics (CRAB) and the biopharmaceutical company Berg Pharma.

Biomarkers are unique biological signatures of the biological processes related to a patient’s cancer that can be used to guide treatments like surgery, radiation and chemotherapy. A physician’s ability to care for pancreatic cancer patients will improve dramatically when biomarkers point the way to medicines that can be used to individualize each patient’s treatment. This is called precision medicine.

Pancreatic cancer is on track to become the second leading cause of cancer death in the United States by 2020, surpassing both colorectal and breast cancer. Currently, only 6.7 percent of pancreatic cancer patients survive for five years, according to the National Cancer Institute.

BIDMC’s Pancreatic Cancer Program is home to one of the nation’s leading clinical and translational research programs for pancreatic cancer.

The BIDMC Cancer Center and PCRT will work together to develop clinical trials of novel new cancer treatments made possible by the Project Survival collaboration.

Our Project Survival Collaborators
  • PCRT is a worldwide group of leading researchers dedicated to finding new treatments for patients with pancreatic cancer. PCRT represents a 48-site multinational network of cancer centers and expert scientists whose mission is to cure pancreatic cancer.
  • Berg Pharma is conducting “pan-omics” (sub-fields within biology) analysis of samples and outcomes from patients treated across the PCRT network to identify potential new biomarkers.
  • CRAB provides “big data” infrastructure for the Project Survival team and coordinates samples and relevant clinical information to validate biomarkers identified by Berg Pharma’s artificial intelligence platform. This “Interrogative Biology” approach can synthesize trillions of data points per sample.